Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)
-
date post
21-Dec-2015 -
Category
Documents
-
view
217 -
download
1
Transcript of Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)
![Page 1: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/1.jpg)
Biomarker studies in advanced breast cancer
Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)
![Page 2: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/2.jpg)
Metastatic Breast Cancer
10% of breast cancer. 30+ patients per year in Colchester
All incurable but median survival 2 to 3 years with current
therapy
Endocrine Therapy Response takes up to 3 months
Chemotherapy Toxic and expensive
![Page 3: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/3.jpg)
STUDY RATIONALE
Novel protein BORIS discovered in WBC of Breast Cancer Patients
Ongoing Study suggests that BORIS could be a Biomarker for response to treatment in Primary Breast Cancer
? Role of BORIS in monitoring response in metastatic breast cancer
? Role in predicting response
Identification of other proteins in metastatic breast cancer
![Page 4: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/4.jpg)
STUDY DESIGN
Endocrine Therapy:
Research Bloods at baseline, 6 weeks and 12 weeks
Clinical assessment, standard blood tests 6 12
Scan , Final clinical assessment 12 week
Chemotherapy:
Research Bloods at baseline, 3 weekly x 6
Clinical assessment, standard blood tests 3 weekly
Scan, post 3 cycles, post 6 cycles
Final clinical assessment post 6 cycles
![Page 5: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/5.jpg)
BIOMARKER BENEFIT
Prediction of response to therapy ER/PR
Monitoring of response to therapy AFP
Prediction of relapse CA 125
![Page 6: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/6.jpg)
Current Status of Project
Target of 30 patients
Patient 31 just enrolled ( in six months)
11 endocrine, 20 chemotherapy
21 patients completed study
50% responding to treatment
50% progressing on treatment
In next 3 months all samples collected and clinical
responses documented
![Page 7: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/7.jpg)
![Page 8: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/8.jpg)
Scientific Perspective
Previous study- BORIS in WBC of breast cancer
patients.
Investigate BORIS in WBC of patients with metastatic
breast disease.
Find a new blood biomarkers to monitor treatment efficacy.
![Page 9: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/9.jpg)
How?
Blood collection Plasm
aWBC
RBC
WBC Plasma
2D gel electrophoresis
Western Blot Analysis
Immunocytochemistry
Abundant protein depletion
Western Blot Analysis
2D gel electrophoresis ?
Cell smearsCell pelletsX
![Page 10: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/10.jpg)
WBC
Boris?
Identify/quantify BORIS levels - monitor pre & during
treatment
Comparison of ‘normal’ versus patient- pre-treatment
Comparison of patient- pre-treatment versus final treatment
New Biomarkers?
Protein Profile of patients WBC
Identify candidate blood biomarkers
![Page 11: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/11.jpg)
Plasma/Serum markers?
Currently used
CEA (Carcineoembryonic antigen)
CA 15.3 (Cancer Antigen breast)
Candidate markers-
- collaborative study with Metodiev group (Uni).
Novel markers?
![Page 12: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/12.jpg)
So far……………..
BORIS?
New biomarker-2D gels?
Normal (healthy)
V
Patient 005
Differences in
protein profile?
Protein ID?Protein absent?
![Page 13: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/13.jpg)
So far……………..
30 patients- 15 analysed pre-treatment.
Candidate novel markers?
Normal ABS 008ABS 009
Protein ID?
![Page 14: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/14.jpg)
Patient 003 –pre-treatment v final treatment
Pre-treatment
Final
Pre-treatment
Final
Protein ID?
Protein ID?
![Page 15: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/15.jpg)
Correlation with clinical data
Chemotherapy or hormone therapy?
Clinical response?
Metastatic disease?
BORIS and/or new biomarker?
![Page 16: Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)](https://reader031.fdocuments.net/reader031/viewer/2022032522/56649d635503460f94a457b9/html5/thumbnails/16.jpg)